S-4512-119
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sponsored by John Kennedy (R-LA)
What it does
The Affordable Insulin Now Act of 2026 would limit what patients pay out of pocket for insulin. Based on the bill's title and prior versions of similar legislation, it would likely cap monthly insulin copayments or cost-sharing for insured patients, potentially extending to both private insurance and federal programs such as Medicare. The full text of the bill has not been published, so specific dollar thresholds and coverage scope are not yet available.
Who benefits
The approximately 8.4 million Americans who use insulin and carry insurance coverage, particularly those currently paying well above any proposed cap. Medicare Part D enrollees and low-income patients on high-deductible plans would likely see the largest reductions. Endocrinologists and diabetes care providers may benefit indirectly if patients are better able to afford and adhere to prescribed treatment. Employers offering group health plans may see reduced absenteeism and complications-related costs if employee adherence improves.
Who is hurt
Insulin manufacturers, who could face indirect pricing pressure or reduced revenue above any cap threshold. Pharmacy benefit managers (PBMs) and insurers, who may absorb costs above the cap and could pass some of those costs on through higher premiums across the broader insured pool. Uninsured patients would not benefit from a copay cap and could be left further behind if the bill does not address list prices. Taxpayers and federal programs would bear costs if the cap applies to Medicare or Medicaid.
Supporters argue
Supporters argue that insulin list prices in the U.S. are roughly 10 times higher than in comparable countries, and that CDC survey data shows one in four insulin-dependent patients rations doses due to cost — a practice linked to hospitalizations and preventable deaths. They contend that the Inflation Reduction Act's $35 Medicare cap demonstrated the policy is workable, and that extending similar protections to private insurance would close a gap that leaves millions of working-age diabetics without meaningful cost relief.
Opponents argue
Opponents argue that copay caps treat a symptom rather than the underlying cause — high list prices set by manufacturers — and that costs above the cap are simply redistributed to all policyholders through higher premiums, as CBO analyses of similar proposals have projected. They contend that without addressing the broader drug pricing and PBM negotiation structure, the bill may reduce incentives for manufacturers to develop next-generation insulin analogs, ultimately harming patients who depend on continued pharmaceutical innovation.
Constitutional context
Congress regulates insurance markets and drug pricing under the Commerce Clause (Art. I, §8, cl. 3) and the Taxing and Spending Clause (Art. I, §8, cl. 1). NFIB v. Sebelius (2012) affirmed broad congressional authority to regulate existing commercial activity in healthcare markets. Post-Loper Bright (2024), any agency rules implementing the cap would face independent judicial review rather than automatic deference, meaning the precise scope of implementing regulations could be contested in court.
Checks and balances
Congress sets the cost-sharing cap by statute; HHS and relevant agencies would implement and enforce regulations; insurers and manufacturers may challenge specific provisions through administrative and judicial review.
Historical precedent
The Inflation Reduction Act of 2022 capped insulin copayments at $35 per month for Medicare Part D enrollees; early CMS data showed measurable reductions in out-of-pocket costs for enrolled seniors.